Regeneron Pharmaceuticals, Inc.
0
0
0%

Financials

Income statement

Fundamentals currency is USD
Fiscal date 2024 2023 2022 2021
Total reported revenue 12.1B 13.1B 12.2B 16.1B
Cost of revenue 1.7B 1.8B 1.6B 2.4B
Gross profit 10.4B 11.3B 10.6B 13.6B
Operating expense
Research & development 4.5B 4.4B 3.6B 2.9B
Selling general and admin 2.5B 2.6B 2.1B 1.8B
Other operating expenses 45.5M -2.1M -89.9M -45.6M
Operating income 3.4B 4.2B 5.0B 9.0B
Non operating interest income
Income 606.5M 495.9M 160.1M 45.8M
Expense 47.1M 73M 59.4M 57.3M
Other income expense 113.4M -456.8M -235.9M 342.5M
Pretax income 4.1B 4.2B 4.9B 9.3B
Tax provision 313.1M 245.7M 520.4M 1.3B
Net income 3.8B 4.0B 4.3B 8.1B
Basic EPS 40.9 37.1 40.5 76.4
Diluted EPS 38.3 34.8 38.2 72.0
Basic average shares 92.0M 111.0M 111.5M 110.0M
Diluted average shares 92.0M 111.0M 111.5M 110.0M
EBITDA 4.4B 5.1B 5.5B 9.3B
Net income from continuing op. 3.8B 4.0B 4.3B 8.1B
Minority interests
Preferred stock dividends
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Market closed

Exchange is currently closed
Pre-market opens in 13 hours 15 minutes

18:44
00:00
08:55
17:35
23:59

Trading Hours (Monday - Friday):

Pre-market
08:00 - 08:55
Main market
08:55 - 17:35
Post-market
17:35 - 17:50
All times are displayed in the Europe/Vienna timezone (CET, UTC+01:00).